RS102895 is a potent CCR2 antagonist used for: inhibiting CCR2-mediated signaling and MCP-1 receptor activity; suppressing extracellular matrix (ECM) protein expression, including fibronectin and type IV collagen, in high glucose-stimulated mesangial cells; reducing TGF-β1 levels in mesangial cells; alleviating bone cancer pain (BCP) in rats via intrathecal administration; and modulating the expression of NR2B, nNOS, and SIGIRR in the spinal cord.